Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
   

 

TTD Drug ID: DCL000009

Drug Information
NameXL418
CompanyExelixis
IndicationSolid Tumors
[ICD9: 140-199, 210-229   ICD10: C00-C75, C7A, C7B, D10-D36, D3A]
Suspended in Phase I    
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
InChI1S/C23H29BrClN7/c1-16-17(5-4-8-30-6-2-3-7-30)13-18(25)14-19(16)31
-9-11-32(12-10-31)23-20-21(24)28-29-22(20)26-15-27-23/h13-15H,2-1
2H2,1H3,(H,26,27,28,29)
InChIKeyQTGCAQPANBHFRY-UHFFFAOYSA-N
Canonical SMILESCC1=C(C=C(C=C1CCCN2CCCC2)Cl)N3CCN(CC3)C4=NC=NC5=NNC(=C54)Br    
Therapeutic ClassAntineoplastic Agents
ClinicalTrials.govNCT00460278;
TargetAKTInhibitor[1]
AKTMultitarget[1]
Ribosomal protein S6 kinaseInhibitor[1]
Ribosomal protein S6 kinaseMultitarget[1]
Ref 1Drug information of XL418. National Cancer Institute. 2009 To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

   
 
 
Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links

 

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543